In my final post about the 2011 American Society of Hematology (ASH) annual meeting, I want to highlight a few of the 4000+ posters that appeared to attract a lot of interest.
The three ASH poster sessions in the equivalent of an aircraft hangar, had a lot of interesting science and clinical data.
All the posters had merit in order to be selected for publication, so my selection is entirely subjective:
Bruton’s Tyrosine Kinase (BTK)
Two posters on products targeting BTK attracted a lot of traffic:
#3485 Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the treatment of B Cell malignancies